Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny, Inc.’s Chief Financial Officer Mark S. Livingston reported routine equity transactions in company common stock. He sold 279 shares in an open-market trade at $26.20 per share, executed under a pre-arranged Rule 10b5-1 trading plan entered into on August 15, 2025.
In a separate entry, 158 shares were withheld at $26.20 per share to cover withholding taxes upon the vesting of restricted stock units granted to him. One line shows 78,905 shares owned after the tax-withholding entry, and another shows 78,626 shares owned after the sale.
Progyny director Scott Cheryl exercised stock options to acquire 14,667 shares of Common Stock at $13.00 per share, then sold 7,439 shares in an open-market transaction at about $26.39 per share. The company withheld 7,228 shares to cover tax obligations, and Cheryl now directly holds 19,772 shares.
Progyny, Inc. Chief Product Officer Geoffrey Clapp reported a combination of equity transactions in common stock. He exercised stock options to acquire 12,909 shares at $20.91 per share and sold 1,530 shares in an open-market transaction at $25.58 per share.
In a separate move, 11,379 shares were withheld to cover withholding taxes upon the vesting of restricted stock units granted to him. After these transactions, he directly holds 59,117 shares of Progyny common stock and 26,211 stock options that are scheduled to expire on March 16, 2035.
Allison Swartz reported proposed sales of company common stock under a Form 144 notice. The filing lists 1199 shares tied to restricted stock vesting to be sold through Fidelity Brokerage Services LLC on 06/03/2026 as compensation-related shares. The excerpt also shows three prior dispositions in the past three months: 4,657 shares (03/03/2026), 599 shares (03/04/2026), and 2,398 shares (05/28/2026).
Mark Livingston submitted a notice under Rule 144 reporting an intended sale of 279 shares of common stock tied to restricted stock vesting on 06/02/2026. The filing also lists a prior sale of 8,275 shares on 05/20/2026 for $211,012.50.
Progyny, Inc. executive vice president and general counsel Allison Swartz reported two transactions in company common stock on May 28, 2026. She completed an open-market sale of 2,398 shares at $25.46 per share under a pre-established Rule 10b5-1 trading plan. Separately, 1,352 shares were withheld to cover withholding taxes upon the vesting of restricted stock units, which is a non-market, compensation-related event. After these transactions, she directly owned 87,589 shares of Progyny common stock.
Cheryl Scott reports a proposed sale of Common stock of PGNY. The filing identifies 2,676 shares linked to a sale dated 06/01/2026 and notes a prior sale of 2,676 shares on 05/22/2026 for $66,177.48. The broker listed is Fidelity Brokerage Services LLC and an option grant date of 10/24/2019 is shown.
Progyny director Kevin K. Gordon reported an open-market sale and related share transfers. On 2026-05-27, he sold 5,500 shares of Progyny common stock at $24.99 per share, leaving 9,318 shares held directly. Separate restructuring transactions moved 2,526 shares from his direct ownership into the Kevin Gordon Revocable Declaration of Trust U/A/D 9/3/2013, which now holds 15,027 shares with Gordon serving as trustee.
PGNY filing of a Form 144 notifies the proposed sale of 2,398 shares of Common Stock by an affiliate on 05/28/2026. The entry lists the method as Restricted Stock Vesting and the purpose as Compensation. The excerpt also discloses prior sales by Allison C. Swartz: 2,199 shares on 03/02/2026, 4,657 shares on 03/03/2026, and 599 shares on 03/04/2026, with the corresponding proceeds reported in the table.